Medically reviewed by Dr. Diala Alatassi, MD — Double Board-Certified in Internal Medicine and Obesity Medicine
Quick answer: There is no oral version of Zepbound® — Zepbound remains a once-weekly injection (tirzepatide). However, Eli Lilly, the maker of Zepbound, received FDA approval on April 1, 2026 for Foundayo™ (orforglipron), a once-daily oral GLP-1 weight loss pill that can be taken any time of day, with or without food. If you were searching for “oral Zepbound,” Foundayo is almost certainly the medication you were looking for.
“Do you have Zepbound in a pill?” It’s one of the most common questions our physicians hear from patients across Chicago — and until this spring, the answer was no. Zepbound has helped many Chicagoland patients achieve substantial weight loss, but the weekly injection isn’t for everyone. Now Eli Lilly has brought its first weight loss pill to market: Foundayo™ (orforglipron), FDA-approved in April 2026 and available to Illinois patients through pharmacies and telehealth evaluation at TeleSlimClinic.com (https://teleslimclinic.com).
Why There’s No “Oral Zepbound” — and What Lilly Made Instead
Zepbound® (tirzepatide) is a dual GIP/GLP-1 receptor agonist — a large peptide molecule that would be broken down in the digestive tract, which is why it’s given as a weekly injection. Rather than reformulating tirzepatide, Eli Lilly developed something different for its pill: orforglipron, a small-molecule (non-peptide) GLP-1 receptor agonist. Because it isn’t a peptide, it survives digestion — which is why Foundayo can be taken at any time of day, with or without food, and with no water restrictions.
On April 1, 2026, the FDA approved Foundayo for adults with obesity, or adults with overweight who have at least one weight-related medical problem, used alongside a reduced-calorie diet and increased physical activity.
Source: Eli Lilly press release, April 1, 2026; Foundayo Prescribing Information.
How Much Weight Loss May Foundayo Provide?
In the phase 3 ATTAIN-1 trial (over 3,100 adults with obesity or overweight, without diabetes), participants taking orforglipron lost an average of up to about 11–12% of their body weight over 72 weeks at the highest dose, versus roughly 2% with placebo, with improvements also seen in waist circumference, blood pressure, and cholesterol.
Setting honest expectations matters, so here’s the straightforward comparison: that’s meaningful, clinically significant weight loss — but it’s less on average than what trials showed for injectable Zepbound (up to the low 20% range) or the oral Wegovy pill (about 13.6–16.6% depending on analysis). What Foundayo trades in average weight loss, it may return in ease of use — and in real-world practice, the medication a patient takes consistently often outperforms a more potent one taken erratically. This is precisely the kind of trade-off worth discussing with an obesity medicine physician rather than deciding from headlines.
Source: ATTAIN-1 trial data; Eli Lilly, April 2026.
Foundayo vs. Zepbound vs. the Wegovy Pill: A Quick Comparison
Foundayo (orforglipron): once-daily pill; taken any time, with or without food; no refrigeration; average weight loss up to about 11–12% in trials; FDA-approved April 2026.
Zepbound (tirzepatide): once-weekly injection; dual GIP/GLP-1 mechanism; the strongest average weight loss of the three in trials; requires refrigerated storage; the right choice for many patients where maximum efficacy is the priority.
Wegovy pill (oral semaglutide): once-daily pill; higher average weight loss than Foundayo in trials, but requires a strict morning routine — empty stomach, plain water only, and a 30-minute wait before food, drink, or other medications.
There is no head-to-head trial comparing the two pills, so cross-trial comparisons are approximate. Which option fits you depends on your health history, your other medications, your routine, and your goals — that’s the evaluation our physicians perform at every consultation.
Safety and Side Effects
The most common side effects reported with Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, gas, and hair loss — with gastrointestinal effects most prominent, particularly during dose increases. As with all GLP-1 medications, Foundayo carries important warnings in its Prescribing Information, and it is not appropriate for everyone — including during pregnancy or in combination with other GLP-1 medications. A full medical evaluation, including your history and current medications, is required before prescribing.
This is not a complete list of side effects or warnings; your physician will review the full safety picture with you.
Source: Foundayo Prescribing Information and Medication Guide, Eli Lilly, 2026.
Availability and Cost in Chicago
Foundayo became available in April 2026 through LillyDirect®, retail pharmacies, and telehealth providers, with Lilly positioning it at a lower cost than injectable GLP-1 therapies. Pricing varies by dose and changes frequently, so we review current self-pay costs and any manufacturer programs with you at your visit — and as a transparent cash-pay practice, TeleSlim’s own fees are flat and disclosed up front.
How Chicago Patients Can Get Evaluated
Book a telehealth consultation at TeleSlimClinic.com (https://teleslimclinic.com) with a board-certified obesity medicine physician. Your visit happens by secure video from anywhere in Illinois. If Foundayo — or another option like the Wegovy pill or an injectable GLP-1 — is medically appropriate for you, your prescription goes to a pharmacy near you, anywhere in Chicagoland or across the state.
Curious whether Foundayo may fit your goals? Book your free consultation here.
Frequently Asked Questions
Q: Is there a pill form of Zepbound?
A: No. Zepbound (tirzepatide) is only available as a once-weekly injection. However, Eli Lilly — the maker of Zepbound — received FDA approval in April 2026 for Foundayo (orforglipron), a once-daily oral GLP-1 weight loss pill.
Q: Is Foundayo the same drug as Zepbound?
A: No. Zepbound contains tirzepatide, a dual GIP/GLP-1 injectable. Foundayo contains orforglipron, a small-molecule GLP-1 taken as a daily pill. They are different medications from the same manufacturer.
Q: How much weight may I lose on Foundayo?
A: In the ATTAIN-1 clinical trial, adults taking the highest dose lost an average of up to about 11–12% of their body weight over 72 weeks. Individual results vary, and results depend on consistent use alongside diet and physical activity changes.
Q: Does Foundayo have food or timing restrictions like the Wegovy pill?
A: No. Per FDA labeling, Foundayo can be taken once daily at any time, with or without food, and without water restrictions — a key practical difference from the Wegovy pill.
Q: Can I switch from Zepbound injections to Foundayo?
A: Possibly — some patients transition between injectable and oral GLP-1 therapies, but switching requires physician guidance, since dosing and expected results differ. Discuss this at your consultation.
Q: Can I get Foundayo through telemedicine in Illinois?
A: Yes. TeleSlim’s board-certified obesity medicine physicians evaluate patients by video anywhere in Illinois and, when medically appropriate, prescribe to a pharmacy near you.
Take the first step today. Book your free consultation here.
This article is for educational purposes and is not medical advice. Foundayo™ and Zepbound® are prescription medications that are not appropriate for everyone; a licensed physician must evaluate whether treatment is right for you. Foundayo™, Zepbound®, and Mounjaro® are trademarks of Eli Lilly and Company; Wegovy® is a registered trademark of Novo Nordisk A/S. TeleSlim Clinic is not affiliated with Eli Lilly or Novo Nordisk.